Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib evaluation in diffuse large B-cell lymphoma
ISRCTN51837425Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2011
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bortezomib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Apr 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN51837425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51837425.